Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Abbott has become the next major diagnostics company to receive an Emergency Use Authorization from the US FDA for a COVID-19 test.
Latest From Innovation
Three-month results of the SPYRAL HTN-OFF MED pivotal trial show renal denervation with Medtronic’s Symplicity Spyral system significantly reduced blood pressure in hypertensive patients not taking anti-hypertensive medications.
Butterfly Network is disseminating the lessons from China and Italy about the poential value of lung ultrasound in the management of COVID-19 patients with respiratory disease.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.
US telehealth companies are seeing skyrocketing demand for devices and services. See what Joseph Brennan, a telehealth expert at Moonshot Health Consulting, said about it here.
US telehealth companies are seeing skyrocketing demand for devices and services, which offers opportunities and challenges during this COVID-19 crisis.
The top official on artificial intelligence products at the US FDA says that while the agency has some authorities to implement regulatory oversight, it may need additional powers from Congress considering the direction the FDA may possibly take in regulating AI and machine learning products.
Edwards’ Pascal transcatheter valve repair devices has been blocked from most use after being found to infringe on Abbott’s patents by a British court.
In this episode of our weekly podcast, Medtech Insight managing editor Marion Webb talks with deputy editor Reed Miller about her story on US hospitals canceling elective surgeries to preserve critical resources in response to COVID-19, and hospitals joining forces with medtechs to find rapid technological solutions to keep patients and caregivers healthy.
US health systems are canceling elective surgeries in response to COVID-19 to preserve critical resources. See what Julian Goldman, anesthesiologist and director of the Medical Device Interoperability and Cybersecurity program at Massachusetts General Hospital, had to say about the potential ramifications.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.